CHEPHASAAR Chemische-Pharmazeutische Fabrik GmbH specializes in the manufacturing and distribution of chemical and pharmaceutical products. The company is part of the MiP Pharma group, which was acquired by capiton AG in November 2020. Following this transaction, a new management team led by Dr. Friedrich Sernetz and Martin Osterhues took over the leadership. The company is based in St. Ingbert and maintains a control and profit transfer agreement with MiP Pharma Holding GmbH.
Gegenstand des Unternehmens sind Herstellung und Vertrieb chemischer und pharmazeutischer Produkte. Die Gesellschaft kann alle Geschäfte betreiben, die dem Gesellschaftszweck unmittelbar oder mittelbar zu dienen geeignet sind. Sie kann Zweigniederlassungen errichten und sich an gleichartigen oder ähnlichen Unternehmen beteiligen
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 32089 (as of 2 November 2026)
| Name | Type | City |
|---|---|---|
| Jürgen Mössinger | Geschäftsführer(in) | Homburg |
| Friedrich Sernetz | Geschäftsführer(in) | Riemerling |
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 32089 (as of 2 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 22.09.2017 | Business Address Registered | Mühlstraße 50, 66386 St. Ingbert |
| 17.11.2003 | Company Name Registered | CHEPHASAAR ChemischePharmazeutische Fabrik, Gesellschaft mit beschränkter Haftung |
| 17.11.2003 | Registered Seat | St.Ingbert |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 17.11.2003 | Share Capital Set | — | 1.790.000 € |
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 32089 (as of 2 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2021 | €408,571 | €0 | €5,840,829 | 1 |
| 2020 | €407,890 | €121,147 | €5,923,260 | 1 |
| 2019 | €407,701 | €0 | €5,773,896 | 1 |
| 2018 | — | €0 | €5,852,770 | 1 |
| 2017 | — | €0 | €5,905,703 | 1 |
| 2016 | — | €0 | €6,002,660 | 1 |
| 2015 | — | €0 | €6,054,289 | — |
| 2014 | — | €0 | €6,241,203 | — |
| 2013 | — | €0 | €6,394,739 | — |
| 2012 | — | €0 | €6,808,374 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Saarbrücken Local Court, HRB 32089 (as of 2 November 2026)
Bionorica SE
Neumarkt · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Baxter Deutschland GmbH
Unterschleißheim · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
SolyPlus GmbH
Haselund · Herstellung von pharmazeutischen Grundstoffen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €625,997 | 75.5% |
| Depreciation | €202,561 | 24.4% |
| Interest & Similar | €483 | 0.1% |
